Securities code: 002513 securities abbreviation: Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) Announcement No.: 2022-006 Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513)
Progress announcement on matters related to the sale of 100% equity of Shaanxi Fangzhou Pharmaceutical Co., Ltd., a wholly-owned subsidiary
The company and all members of the board of supervisors guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
1、 Arrears of Shaanxi Fangzhou Pharmaceutical Co., Ltd
Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) (hereinafter referred to as “the company” or “the company”) signed the equity transfer agreement with Beijing Jikang Ruisheng Health Technology Co., Ltd. (hereinafter referred to as “Jikang Ruisheng”, formerly known as “Beijing Zhongyu Diaolong Medical Information Technology Co., Ltd.) on November 30, 2020, Transfer 100% equity of Shaanxi Fangzhou Pharmaceutical Co., Ltd. (hereinafter referred to as “Fangzhou pharmaceutical”), a wholly-owned subsidiary of Jikang Ruisheng, with a total equity transfer price of 450 million yuan. The company held the ninth meeting of the Fifth Board of directors and the eighth meeting of the Fifth Board of supervisors on December 3, 2020, and the first extraordinary general meeting of shareholders in 2020 on December 21, 2020. The above matters were considered and approved. For details, see the relevant announcements disclosed in the designated information disclosure media on December 5, 2020 and December 22, 2020.
On December 15, 2020, the company received the attention letter on Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) issued by the management department of small and medium-sized board company of Shenzhen Stock Exchange (small and medium-sized board attention letter [2020] No. 585). It was concerned that Fangzhou pharmaceutical still owed the company 24.3 million yuan as of December 10, 2020, and both parties negotiated to return the above amount before December 31, 2021, The company is required to supplement whether Fangzhou pharmaceutical has the ability to repay in full, whether there are repayment arrangements and specific measures to improve its debt repayment guarantee ability. On December 17, 2020, after careful discussion and analysis and active consultation with Jikang Ruisheng, the company made the following arrangements for the current accounts owed by Fangzhou pharmaceutical:
Jikang Ruisheng will improve the financial situation of Fangzhou Pharmaceutical by improving operation and injecting liquidity after the industrial and commercial change of Fangzhou pharmaceutical’s equity transfer, and promote Fangzhou pharmaceutical to repay the above arrears according to the following repayment plan:
1. Return 2 million yuan before March 31, 2021;
2. Return 5 million yuan before June 30, 2021;
3. Return 8 million yuan before September 30, 2021;
4. Return 9.3 million yuan before December 31, 2021.
Meanwhile, Jikang Ruisheng guarantees that Fangzhou pharmaceutical will repay on schedule according to the above repayment plan and will provide joint and several guarantee liabilities for the repayment of the above arrears.
For the above contents, please refer to the announcement on reply to the letter of concern of Shenzhen Stock Exchange (Announcement No.: 2020-070) disclosed by the company in the designated information disclosure media on December 19, 2020.
2、 Repayment progress
On March 31, 2021, the company received a repayment of 2 million yuan from Fangzhou pharmaceutical. For details, see the progress announcement on Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) issues related to the sale of 100% equity of wholly-owned subsidiary Shaanxi Fangzhou Pharmaceutical Co., Ltd. (Announcement No.: 2021-013) disclosed by the company in the designated information disclosure media on April 13, 2021.
On June 30, 2021, the company received a repayment of 5 million yuan from Fangzhou pharmaceutical. See Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) progress announcement on issues related to the sale of 100% equity of wholly-owned subsidiary Shaanxi Fangzhou Pharmaceutical Co., Ltd. (Announcement No.: 2021-054) disclosed by the company in the designated information disclosure media on July 2, 2021.
On September 30, 2021, the company received a repayment of 8 million yuan from Fangzhou pharmaceutical. See Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) progress announcement on issues related to the sale of 100% equity of wholly-owned subsidiary Shaanxi Fangzhou Pharmaceutical Co., Ltd. (Announcement No.: 2021-067) disclosed by the company in the designated information disclosure media on October 8, 2021.
On December 30, 2021, the company received a repayment of 9.3 million yuan from Fangzhou pharmaceutical.
Up to now, the company has received a total repayment of 24.3 million yuan from Fangzhou pharmaceutical, and all the arrears have been repaid.
3、 Documents for future reference
1. Remittance form of Shaanxi Fangzhou Pharmaceutical Co., Ltd.
It is hereby announced.
Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) board of directors December 31, 2021
